Journey patent expiration
1. Amzeeq patent expiration
Can you believe AMZEEQ received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10821187 | JOURNEY | Compositions, gels and foams with rheology modulators and uses thereof |
Oct, 2030
(6 years from now) | |
| US8945516 | JOURNEY | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
Oct, 2030
(6 years from now) | |
| US10265404 | JOURNEY | Compositions, gels and foams with rheology modulators and uses thereof |
Oct, 2030
(6 years from now) | |
| US10137200 | JOURNEY | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
Oct, 2030
(6 years from now) | |
| US8865139 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(6 years from now) | |
| US9675700 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(6 years from now) | |
| US8992896 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(6 years from now) | |
| US10086080 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(6 years from now) | |
| US10517882 | JOURNEY | Method for healing of an infected acne lesion without scarring |
Oct, 2030
(6 years from now) | |
| US10213512 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(6 years from now) | |
| US10398641 | JOURNEY | Compositions and methods for treating rosacea and acne |
Sep, 2037
(13 years from now) | |
| US10849847 | JOURNEY | Compositions and methods for treating rosacea and acne |
Sep, 2037
(13 years from now) | |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 October, 2019
Treatment: Treatment of non-nodular acne vulgaris
Dosage: AEROSOL, FOAM
How can I launch a generic of AMZEEQ before it's drug patent expiration?
More Information on Dosage
AMZEEQ family patents
2. Qbrexza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10548875 | JOURNEY | Glycopyrrolate salts |
Feb, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6433003 | JOURNEY | Method for treating hyperhidrosis in mammals |
Apr, 2020
(4 years ago) | |
| US10052267 | JOURNEY | Topical glycopyrrolate formulations |
Oct, 2028
(4 years from now) | |
| US8618160 | JOURNEY | Topical glycopyrrolate formulations |
Dec, 2029
(5 years from now) | |
| US9744105 | JOURNEY | Topical glycopyrrolate formulations |
Jul, 2030
(5 years from now) | |
| US9259414 | JOURNEY | Glycopyrrolate salts |
Feb, 2033
(8 years from now) | |
| US10543192 | JOURNEY | Glycopyrrolate salts |
Feb, 2033
(8 years from now) | |
| US10004717 | JOURNEY | Glycopyrrolate salts |
Feb, 2033
(8 years from now) | |
| US9006462 | JOURNEY | Glycopyrrolate salts |
Feb, 2033
(8 years from now) | |
| US8859610 | JOURNEY | Crystalline glycopyrrolate tosylate |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 28, 2021 |
Drugs and Companies using GLYCOPYRRONIUM TOSYLATE ingredient
Market Authorisation Date: 28 June, 2018
Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
Dosage: CLOTH
How can I launch a generic of QBREXZA before it's drug patent expiration?
More Information on Dosage
QBREXZA family patents
3. Ximino patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5908838 | JOURNEY | Method for the treatment of acne |
Feb, 2018
(6 years ago) | |
| US8268804 | JOURNEY | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(9 months from now) | |
| US7790705 | JOURNEY | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(9 months from now) | |
| US8252776 | JOURNEY | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(9 months from now) | |
| US7919483 | JOURNEY | Method for the treatment of acne |
Mar, 2027
(2 years from now) | |
| US7544373 | JOURNEY | Minocycline oral dosage forms for the treatment of acne |
Apr, 2027
(2 years from now) | |
| US7541347 | JOURNEY | Minocycline oral dosage forms for the treatment of acne |
Apr, 2027
(2 years from now) | |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 11 July, 2012
Treatment: Treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris; Treatment of acne
Dosage: CAPSULE, EXTENDED RELEASE
More Information on Dosage
XIMINO family patents
4. Zilxi patent expiration
Can you believe ZILXI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10265404 | JOURNEY | Compositions, gels and foams with rheology modulators and uses thereof |
Oct, 2030
(6 years from now) | |
| US10213512 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(6 years from now) | |
| US8992896 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(6 years from now) | |
| US9675700 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(6 years from now) | |
| US8865139 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(6 years from now) | |
| US10322186 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(6 years from now) | |
| US10946101 | JOURNEY | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
Oct, 2030
(6 years from now) | |
| US8945516 | JOURNEY | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
Oct, 2030
(6 years from now) | |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 May, 2020
Treatment: Treatment of inflammatory lesions of rosacea.
Dosage: AEROSOL, FOAM
How can I launch a generic of ZILXI before it's drug patent expiration?
More Information on Dosage
ZILXI family patents